Artrodar Side Effects

The safety of ARTRODAR has been evaluated in over 5,000 patients in clinical studies. 6% of the patients stopped treatment due to adverse reactions.
Gastrointestinal effects: Diarrhoea, abdominal pain, frequent bowel movements and flatulence are the most frequently reported side effects associated with ARTRODAR treatment. As a rule, these effects abate with continuing treatment. In some cases, diarrhoea was severe with complications such as dehydration and disorders of fluid and electrolyte balance. The intake of the drug with meals or starting treatment with half the recommended daily dose (50 mg/day) could decrease the incidence of these events. A pigmentation of the recto-colic mucosa (melanosis coli) has been observed rarely (1-10% of the patients).
Renal and urinary changes: A dark colouration of the urine may be observed. This is due to the structure of the molecule and is of no clinical significance (>10% of the patients).
Hepatobiliary disorders: Cases of acute liver injury, including elevated serum hepatic enzymes and cases of hepatitis have been reported in the post-marketing phase with diacerein. Most of them occurred during the first months of treatment. Patients should be monitored for signs and symptoms of hepatic injury (see Precautions).
Effects on the skin and subcutaneous tissue: Some cases of pruritus, eczema and cutaneous eruptions have been reported (1-10% of the patients).